Patients with Sepsis and Coagulopathy Didn't Benefit from a Novel Anticoagulant

Recombinant human soluble thrombomodulin caused excess bleeding.

Based on a single 2001 study, the U.S. FDA approved recombinant activated protein C (drotrecogin alfa; Xigris) for patients with severe sepsis (NEJM JW Gen Med Apr 15 2001 and N Engl J Med 2001; 344:699). However, after multiple subsequent trials showed higher rates of bleeding in drotrecogin-treated patients and no mortality benefit, it was taken off the market (NEJM JW Gen Med Aug 15 2012 and N Engl J Med 2012; 366:2055).

Now, a different agent that affects the same pathway has been considered for a more-select population of patients with sepsis. Recombinant human soluble thrombomodulin (rhsTM) binds thrombin and serves as an activation complex to convert protein C to activated protein C. This effect might mitigate the coagulopathy of seps…

Reviewing Author

Patricia Kritek, MD

Disclosures

Editorial BoardsATS Scholar

Patricia Kritek, MD

Disclosures

Editorial BoardsATS Scholar

Patients with Sepsis and Coagulopathy Didn't Benefit from a Novel Anticoagulant

Topics

Reviewing Author